ARGX $542.47

ARGX·NASDAQargenx SE

$542.47-18.43 (-3.29%)·Pre-Market: $545.13+2.66 (+0.49%)

May 14, 2025 at 08.12

Candle Chart

Open557.37

High557.37

Low538.09

Vol685921

P/E33.11783

Mkt cap34.19B

52W H678.21

52W L356.38

Avg Vol407130

Div yieldN/A

Beta0.17

EPS16.38

Short Term High Open Interest Options

ContractARGX May 16 2025 640 Call

Expiry2025-05-16

TypeCALL

Strike$640

Open Interest1130

Last Price$0.06

LEAP High Open Interest Options

ContractN/A

ExpiryN/A

TypeN/A

StrikeN/A

Open InterestN/A

Last PriceN/A

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren'...

Sector: Healthcare

Industry: Biotechnology

Country: Netherlands

Employees: 1,599

Website: https://argenx.com

See More Data from Yahoo Finance

Insider Monkey - 6 hours agoargenx SE (ARGX): Among the Best Growth Stocks to Buy and Hold for the Long Term2025-05-14T02:16:36.000Z MT Newswires - 20 hours agoBaird Upgrades argenx to Outperform From Neutral, Price Target is $6802025-05-13T11:29:14.000Z Zacks - 1 days agoArgenx (ARGX) Upgraded to Buy: Here's Why2025-05-12T16:00:08.000Z MT Newswires - 17 hours agoEuropean Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading2025-05-13T15:09:29.000Z Insider Monkey - 4 days agoargenx SE (ARGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain2025-05-09T14:25:17.000Z